Exhibit 10.1


 





Execution Version




 


INVESTORS’
RIGHTS AGREEMENT


 


BY AND BETWEEN


 


ACTINIUM PHARMACEUTICALS, INC.


 


AND


 


MEMORIAL SLOAN KETTERING CANCER CENTER


 






    


     


    

 





TABLE
OF CONTENTS


 




	1.   Definitions	1
	2.   Registration Rights	3
	2.1   Demand Registration	3
	2.2   Piggyback Registration	4
	2.3   Underwriting Requirements	4
	2.4   Obligations of the Company	5
	2.5   Furnish Information	6
	2.6   Expenses of Registration	6
	2.7   Delay of Registration	7
	2.8   Indemnification	7
	2.9   Reports Under Exchange Act	9
	2.10   Restrictions on Transfer	9
	2.11   Termination of Registration Rights	11
	3.   Confidentiality and Publicity	11
	3.1   Confidentiality	11
	3.2   Publicity	12
	4.   Prescribed Activity	12
	4.1   Standstill	12
	4.2   Voting	13
	5.   Miscellaneous	13
	5.1   Successors and Assigns	13
	5.2   Governing Law	13
	5.3   Counterparts	13
	5.4   Titles and Subtitles	14
	5.5   Notices	14
	5.6   Amendments and Waivers	15
	5.7   Severability	15
	5.8   Aggregation of Stock	15
	5.9   Entire Agreement	15
	5.10   Dispute Resolution	16
	5.11   Delays or Omissions	16
	5.12   Interpretation	16


 


Exhibit A     -     Form of Press Release


 






    i


     


    

 




INVESTORS’
RIGHTS AGREEMENT


 


THIS
INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the 21st day of December, 2015,
by and between Actinium Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Memorial Sloan Kettering
Cancer Center, a New York not-for-profit corporation (“MSKCC”).


 


RECITALS


 


WHEREAS,
MSKCC holds shares of the Company’s Common Stock; and


 


WHEREAS,
MSKCC and the Company agree that this Agreement shall govern certain liquidity matters and certain other matters as set forth
herein.


 


NOW,
THEREFORE, the parties to this Agreement hereby agree as follows:


 


1.            Definitions. For purposes of this Agreement:


 


1.1          “Agreement” shall have the meaning set forth in the Preamble.


 


1.2          “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls,
is controlled by, or is under common control with such Person, including any general partner, managing member, officer or director
of such Person.


 


1.3          
“Common Stock” means shares of the Company’s common stock, par value $0.001 per share.


 


1.4          
“Company” has the meaning set forth in the Preamble.


 


1.5          
“Confidential Information” has the meaning set forth in Section 3.1.


 


1.6          
“Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may become
subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability
(or any action in respect thereof) arises out of or is based upon: (i) any untrue statement or alleged untrue statement of a material
fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained
therein or any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a material fact required
to be stated therein, or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation
by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state
securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law.


 


1.7          
“Demand Notice” has the meaning set forth in Section 2.1(a).


 



    


     


    

 


1.8          “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
thereunder.


 


1.9          “Excluded Registration” means (i) a registration relating to the sale of securities to employees of the Company
or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction;
(iii) a registration on any form that does not include substantially the same information as would be required to be included
in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common Stock
being registered is Common Stock issuable upon conversion of debt securities that are also being registered.


 


1.10         “Form S-3” means such form under the Securities Act as in effect on the date hereof or any registration form
under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to
other documents filed by the Company with the SEC.


 


1.11         “Holder” means any holder of Registrable Securities who is a party to this Agreement.


 


1.12         “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this Agreement.


 


1.13         “MSKCC” has the meaning set forth in the Preamble.


 


1.14         “Person” means any individual, corporation, partnership, trust, limited liability company, association or other
entity.


 


1.15         “Plan” has the meaning set forth in Section 4.2.


 


1.16         “Pre-Registation Period” has the meaning set forth in Section 2.10(a).


 


1.17         “Registrable Securities” means (i) the five million, seven hundred and two thousand, three hundred and eighty
seven (5,702,387) shares of Common Stock held by MSKCC on the date hereof; and (ii) any Common Stock issued as (or issuable upon
the conversion or exercise of any warrant, right, or other security that is issued as) a dividend or other distribution with respect
to, or in exchange for or in replacement of, the shares referenced in clause (i) above; excluding in all cases, however,
any Registrable Securities sold by MSKCC in a transaction in which the applicable rights under this Agreement are not assigned
pursuant to Section 5.1, and excluding for purposes of Section 2 (but not Section 2.9 or 2.10) any
shares for which registration rights have terminated pursuant to Section 2.11 of this Agreement.


 


1.18         “Representative” means, as to any Person, such Person’s Affiliates, and its and their respective directors,
officers, employees, managing members, general partners, agents and consultants (including attorneys, financial advisors and accountants).


 



    2


     


    

 


1.19         “SEC” means the Securities and Exchange Commission.


 


1.20         “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act.


 


1.21         “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act.


 


1.22         “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.


 


1.23         “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable
to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements
of the Selling Holder Counsel borne and paid by the Company as provided in Section 2.6.


 


1.24         “Selling Holder Counsel” has the meaning set forth in Section 2.6.


 


1.25         “Subject Information” has the meaning set forth in Section 3.2.


 


2.            Registration Rights. The Company covenants and agrees as follows:


 


2.1           Demand Registration.


 


 (a)            Form S-3 Demand. If at any time after December 31, 2016, the Company receives a request from Holders of at least a majority
of the Registrable Securities then outstanding that the Company file a Form S-3 registration statement with respect to outstanding
Registrable Securities of such Holders, then the Company shall (i) within ten (10) days after the date such request is given,
give notice thereof (the “Demand Notice”) to all Holders other than the Initiating Holders; and (ii) as soon
as practicable, and in any event within forty-five (45) days after the date such request is given by the Initiating Holders, file
a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such
registration by the Initiating Holders and any other Holders, as specified by notice given by each such Holder to the Company
within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Section 2.1(b).


 


 (b)           Notwithstanding the foregoing obligations, if the Company furnishes to the Holders requesting a registration pursuant to
this Section 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith
judgment of the Company’s Board of Directors it would be materially detrimental to the Company and its stockholders for
such registration statement to either become effective or remain effective for as long as such registration statement
otherwise would be required to remain effective, because such action would (i) materially interfere with a significant
acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure
of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii) render the
Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to
defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness thereof shall
be tolled correspondingly, for a period of not more than ninety (90) days after the request of the Initiating Holders is
given; provided, however, that the Company may not invoke this right more than once in any twelve (12) month
period; and provided further that the Company shall not register any securities for its own account or that of
any other stockholder during such ninety (90) day period other than an Excluded Registration.


 



    3


     


    

 


 (c)          
The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Section 2.1(a)
(i) during the period that is thirty (30) days before the Company’s good faith estimate of the date of filing of, and
ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration, provided that
the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become
effective; or (ii) if the Company has effected two registrations pursuant to Section 2.1(a) within the twelve (12) month
period immediately preceding the date of such request. A registration shall not be counted as “effected” for purposes
of this Section 2.1(c) until such time as the applicable registration statement has been declared effective by the SEC,
unless, subject to Section 2.6, the Initiating Holders withdraw their request for such registration and elect not to pay
the registration expenses therefor, in which case such withdrawn registration statement shall be counted as “effected”
for purposes of this Section 2.1(c).


 


2.2           Piggyback Registration. If the Company proposes to register (including, for this purpose, a registration effected by the
Company for stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public
offering of such securities solely for cash (other than in an Excluded Registration), (i) by the Company for its own account as
to which any of the Company’s stockholders participate as selling stockholders or (ii) by the Company for the account of
other stockholders, the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of
each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the provisions
of Section 2.3, cause to be registered all of the Registrable Securities that each such Holder has requested to be included
in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Section
2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities
in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company
in accordance with Section 2.6.


 


2.3           Underwriting Requirements.


 


 (a)           In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to Section
2.2, the Company shall not be required to include any of the Holder’s Registrable Securities in such underwriting unless
the Holders accept the terms of the underwriting as agreed upon between the Company (acting reasonably) and its underwriters,
and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering
by the Company. If the total number of securities, including Registrable Securities, requested by stockholders to be included
in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable
discretion determine is compatible with the success of the offering, then the Company shall be required to include in the offering
only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion
determine will not jeopardize the success of the offering. Notwithstanding the foregoing, (x) in no event shall the Registrable
Securities included in the offering be reduced by a greater percentage than the bona fide securities sought to be included in
such offering by any other selling shareholder and (y) in no event shall the number of Registrable Securities included in the
offering be reduced below twenty percent (20%) of the total number of securities included in such offering.


 



    4


     


    

 


2.4            Obligations of the Company. Whenever required under this Section 2 to effect the registration of any Registrable
Securities, the Company shall, as expeditiously as reasonably possible:


 


 (a)            prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable
Securities registered thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days
or, if earlier, until the distribution contemplated in the registration statement has been completed; provided, however,
that (i) such one hundred twenty (120) day period shall be extended for a period of time equal to the period the Holders refrain,
at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in
such registration, and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended by the Holders
to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120)
day period shall be extended for up to ninety (90) days, if necessary, to keep the registration statement effective until all
such Registrable Securities are sold;


 


 (b)           prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection
with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of
all securities covered by such registration statement;


 


 (c)           furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the
Securities Act, and such other documents as the selling Holders may reasonably request in order to facilitate their disposition
of their Registrable Securities;


 


 (d)          
use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such
other securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided
that the Company shall not be required to qualify to do business or to file a general consent to service of process in any such
states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by
the Securities Act;


 


 (e)          
in the event of any underwritten public offering (whether on an “all or none basis”, “best efforts basis”
or otherwise), enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the underwriter(s)
of such offering;


 


 (f)          
use its commercially reasonable efforts to cause all such Registrable Securities covered by such registration statement to be
listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar
securities issued by the Company are then listed;


 



    5


     


    

 


 (g)          provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP
number for all such Registrable Securities, in each case not later than the effective date of such registration;


 


 (h)           promptly make available for inspection by the selling Holders, any managing underwriter(s) participating in any disposition pursuant
to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by
the selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause
the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested
by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy
of the information in such registration statement and to conduct appropriate due diligence in connection therewith;


 


 (i)            notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has
been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and


 


 (j)           after such registration statement becomes effective, promptly notify each selling Holder of any request by the SEC that the Company
amend or supplement such registration statement or prospectus.


 


2.5          Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action pursuant to
this Section 2 with respect to the Registrable Securities of any selling Holder that such selling Holder shall furnish
to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition
of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities.


 


2.6          Expenses of Registration. All expenses (other than Selling Expenses) incurred in connection with registrations, filings,
or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and
accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements, not to exceed fifteen
thousand dollars ($15,000) per registration, of one counsel for the selling Holders (“Selling Holder Counsel”),
shall be borne and paid by the Company; provided, however, that the Company shall not be required to pay for any
expenses of any registration proceeding begun pursuant to Section 2.1 if the registration request is subsequently withdrawn
at the request of the Initiating Holders; provided, further, that if, at the time of such withdrawal, the Holders
shall have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the
Holders at the time of their registration request and have withdrawn the request with reasonable promptness after learning of
such information then the Holders shall not be required to pay any of such expenses and the withdrawal shall not be deemed to
result in an “effected” registration for purposes of Section 2.1(c). All Selling Expenses relating to Registrable
Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number
of Registrable Securities registered on their behalf.


 



    6


     


    

 


2.7           Delay of Registration. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying
any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation
or implementation of this Section 2.


 


2.8           Indemnification. If any Registrable Securities are included in a registration statement under this Section 2:


 


 (a)          To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members, officers,
directors, and stockholders of such Holder; legal counsel and accountants for such Holder; any underwriter (as defined in the
Securities Act) for such Holder; and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities
Act or the Exchange Act, against any Damages, and the Company will pay to such Holder, underwriter, controlling Person, or other
aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any
claim or proceeding from which Damages may result, as such expenses are incurred; provided, however, that the indemnity
agreement contained in this Section 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding
if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall
the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance
upon and in conformity with written information furnished by or on behalf of such Holder, or its underwriter, controlling Person,
or other aforementioned Person connected with such Holder expressly for use in connection with such registration.


 


 (b)           To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company,
and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls
the Company within the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined
in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any
such underwriter or other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based
upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such indemnifying
selling Holder expressly for use in connection with such registration; and each such indemnifying selling Holder will pay to the
Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating
or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however,
that the indemnity agreement contained in this Section 2.8(b) shall not apply to amounts paid in settlement of any such
claim or proceeding if such settlement is effected without the consent of the indemnifying Holder, which consent shall not be
unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by
way of indemnity or contribution under Section 2.8(b) and 2.8(d) exceed the proceeds from the offering received
by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder.


 



    7


     


    

 


 (c)           Promptly after receipt by an indemnified party under this Section 2.8 of notice of the commencement of any action
(including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will,
if a claim in respect thereof is to be made against any indemnifying party under this Section 2.8, give the indemnifying
party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the
extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been given,
and to assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an
indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall
have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation
of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential
differing interests between such indemnified party and any other party represented by such counsel in such action. The failure
to give notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying
party of any liability to the indemnified party under this Section 2.8, to the extent that such failure materially prejudices
the indemnifying party’s ability to defend such action. The failure to give notice to the indemnifying party will not relieve
it of any liability that it may have to any indemnified party otherwise than under this Section 2.8.


 


 (d)          To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either: (i) any
party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.8 but
it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration
of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding
the fact that this Section 2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act
may be required on the part of any party hereto for which indemnification is provided under this Section 2.8, then, and
in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they
may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of
the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted
in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative
fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether
the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to
information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge,
access to information, and opportunity to correct or prevent such statement or omission; provided, however, that,
in any such case (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable
Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation
(within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty
of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant
to this Section 2.8(d), when combined with the amounts paid or payable by such Holder pursuant to Section 2.8(b),
exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the
case of willful misconduct or fraud by such Holder.


 



    8


     


    

 


 (e)           Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the
underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing
provisions, the provisions in the underwriting agreement shall control.


 


 (f)           Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the
obligations of the Company and Holders under this Section 2.8 shall survive the completion of any offering of Registrable
Securities in a registration under this Section 2, and otherwise shall survive the termination of this Agreement.


 


2.9           Reports Under Exchange Act. With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule
or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration
or pursuant to a registration on Form S-3, the Company shall:


 


 (a)           make and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all
times;


 


 (b)          use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company
under the Securities Act and the Exchange Act; and


 


 (c)           furnish to any Holder, so long as such Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate,
a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144, the Securities Act, and
the Exchange Act and that it qualifies as a registrant whose securities may be resold pursuant to Form S-3; and (ii) such other
information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling
of any such securities without registration or pursuant to Form S-3.


 


2.10         Restrictions on Transfer.


 


 (a)           Commencing from the date hereof until the earlier to occur of (i) March 31, 2016 and (ii) the start of the Actimab-A Phase 2 clinical
study (the “Pre-Registration Period”), each Holder agrees not to make any sale, assignment, transfer, pledge
or other disposition of all or any portion of the Registrable Securities, except pursuant to a registered offering under Section
2.2; provided, that no officers or directors of the Company (or any Affiliates of such officers or directors, any immediate
family members of such officers or directors, or any trusts formed for the benefit of any of the foregoing) shall sell, assign,
transfer, pledge or otherwise dispose of any Common Stock during the Pre-Registration Period.


 


 (b)          From and after the Pre-Registration Period until December 31, 2016, each Holder agrees that (i) no more than seventy five percent
(75%) of the Registrable Securities outstanding as of the date hereof may be sold, assigned, transferred, pledged, or otherwise
disposed of (including, pursuant to a registered offering under Section 2.2) and (ii) except pursuant to a registered offering
under Section 2.2, no more than one hundred fifty thousand (150,000) shares of Registrable Securities (subject to appropriate
adjustment for stock splits, stock dividends, combinations, and other recapitalizations) may be sold, assigned, transferred, pledged
or otherwise disposed of in any calendar week; provided, that such one hundred fifty thousand (150,000) share allotment
shall be increased to the extent of the aggregate unused allotment from all prior calendar weeks; provided, further,
that, except pursuant to a registered offering under Section 2.2, in no event after giving effect to any such increase
shall more than two hundred fifty thousand (250,000) shares of Registrable Securities (subject to appropriate adjustment for stock
splits, stock dividends, combinations, and other recapitalizations) be sold, assigned, transferred, pledged or otherwise disposed
in any calendar week.


 



    9


     


    

 


 (c)           For the avoidance of doubt, except for the
restrictions contained in Sections 2.10(a) and 2.10(b), there shall be no other restriction imposed by the Company
on the ability to sell, assign, transfer, pledge or otherwise dispose of Registrable Securities.


 


 (d)          Any transfer or purported transfer of the Registrable Securities in violation of this Section 2.10 shall be void ab initio.
The Company shall not be required to register any transfer of the Registrable Securities in violation of this Section 2.10.
The Company may, and may instruct any transfer agent for the Company, to place such stop transfer orders as may be required on
the transfer books of the Company in order to ensure compliance with the provisions of this Section 2.10.


 


 (e)           Each certificate, instrument, or book entry representing (i) the Registrable Securities, and (ii) any other securities issued
in respect of the securities referenced in clause (i), upon any stock split, stock dividend, recapitalization, merger, consolidation,
or similar event, shall be notated with a legend as follows:


 


THE
SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
OR ANY APPLICABLE STATE SECURITIES LAWS. THE SHARES HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES ONLY AND NOT WITH A VIEW TOWARD
RESALE AND MAY NOT BE OFFERED, SOLD, DELIVERED AFTER SALE, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED IN THE
ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FILED BY THE ISSUER WITH THE U.S. SECURITIES AND EXCHANGE COMMISSION COVERING THE
SHARES UNDER THE SECURITIES ACT OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF SAID ACT THAT IS THEN APPLICABLE TO THE
SHARES. AN OPINION OF COUNSEL SATISFACTORY TO THE ISSUER IN RESPECT OF THE FOREGOING MAY BE REQUIRED BY THE ISSUER OR THE TRANSFER
AGENT.


 


The
Holders consent to the Company making a notation in its records and giving instructions to any transfer agent of the Registrable
Securities in order to implement the restrictions on transfer set forth in this Section 2.10.


 



    10


     


    

 


 (f)           Subject to compliance with the proviso in this Section 2.10(f) below, the Company will (i) promptly remove any restrictive
legends on certificates representing the Registrable Securities, (ii) upon request of any Holder, make the Company’s counsel
available to participate in any due diligence calls with such Holder’s brokers and (iii) employ the Company’s counsel
(at the Company’s expense) to prepare any legal opinion necessary for the prompt removal of such restrictive legends; provided,
in each case (x) such legends may be removed in reliance on SEC Rule 144 or otherwise in compliance with any other applicable
laws, (y) such Holder provides to the Company and/or its counsel such supporting documentation as is customarily provided in connection
with such legend removal and (z) such Holder is then in compliance with its obligations under this Agreement.


 


2.11         Termination
of Registration Rights. The right of any Holder to request registration or inclusion of Registrable Securities in any registration
pursuant to Sections 2.1 or 2.2 shall terminate upon the earlier to occur of (a) such time as (i) SEC Rule 144 or
another similar exemption under the Securities Act is available for the sale of all of such Holder’s shares of Registrable
Securities without volume limitation, (ii) the Company shall have removed all restrictive legends on certificates representing
such Holder’s shares of Registrable Securities and (iii) such Holder holds fewer than five hundred thousand (500,000) shares
of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations)
and (b) December 31, 2019.


 


3.          Confidentiality
and Publicity.


 


3.1           Confidentiality. Each Holder agrees that it will keep confidential and will not disclose, divulge, or use for any purpose
(other than to monitor its investment in the Company) (a) any notices of proposed registration provided by the Company to such
Holder pursuant to Section 2.2, and (b) any information contained to the extent necessary in any registration statement
or prospectus (including drafts thereof) provided by the Company to such Holder in connection with any registration of its shares
pursuant to Section 2.1 or 2.2. (together with (a), “Confidential Information”), unless
such Confidential Information (i) is known or becomes known to the public in general (other than as a result of a breach of this
Section 3.1 by such Holder), (ii) is or has been independently developed or conceived by such Holder without use of the
Company’s Confidential Information, or (iii) is or has been made known or disclosed to such Holder by a third party without,
to the knowledge of such Holder, a breach of any obligation of confidentiality such third party may have to the Company; provided,
however, that such Holder may disclose Confidential Information (x) to its attorneys, accountants, consultants, and other
professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (y)
to any Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Holder in the ordinary course of business,
provided that such Holder informs such Person that such information is confidential and directs such Person to maintain
the confidentiality of such information; or (z) as may otherwise be required by law, provided that, to the extent reasonable
and practicable, such Holder promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent
of any such required disclosure. The Company shall not furnish to any Holder (without such Holder’s prior written consent)
any material non-public information concerning the Company other than any such information required to be provided to such Holder
pursuant to the terms of this Agreement.


 



    11


     


    

 


3.2           Publicity. The Company and MSKCC will issue a joint press release announcing entry into this Agreement, in the form attached
hereto as Exhibit A. MSKCC shall have the right to review and approve (such approval not be unreasonably withheld, delayed
or conditioned) the Company’s 8-K filing disclosing the joint press release and this Agreement. The Company shall have the
right to review and approve (such approval not to be unreasonably withheld, delayed or conditioned) MSKCC’s amendment to
its Schedule 13D disclosing the joint press release and this Agreement. Unless specifically approved by both the Company and MSKCC
in writing, and except to the extent of any filings with (or submissions to) any court of law in connection with the enforcement
of any rights or exercise of remedies under this Agreement, no party shall make any public disclosure concerning the terms of,
circumstances of, or otherwise as to, this Agreement (collectively, “Subject Information”) that is inconsistent
with, or provides information as to Subject Information that is in addition to, or contains a material omission relative to, that
provided in, (a) the joint press release or (b) this Agreement. For the avoidance of doubt, the provisions contained in this Section
3.2 shall relate solely to the Subject Information and shall not amend or otherwise modify any other agreement between the
parties restricting publicity as to any other information.


 


4.           
Prescribed Activity.


 


4.1           Standstill. So long as the Company is in compliance with its obligations under this Agreement, then unless approved in
advance by the Board of Directors of the Company, each Holder agrees that neither it nor any of its Representatives acting on
behalf of such Holder will, for a period ending immediately after the annual shareholders meeting of the Company in 2016 (and
in all events no later than December 31, 2016), directly or indirectly:


 


 (a)           make any proposal to the Board of Directors of the Company, any of the Company’s Representatives or
any of the Company’s stockholders regarding, or make any public announcement, proposal or offer (including “solicitation”
of “proxies” as such terms are defined or used in Regulation 14A of the Exchange Act) offering (i) any business combination,
merger, tender offer, exchange offer or similar transaction involving the Company or any of its subsidiaries, (ii) any restructuring,
recapitalization, liquidation or similar transaction involving the Company or any of its subsidiaries, except in each case solely
in connection with contractual arrangements between MSKCC and the Company or its then existing subsidiaries, (iii) any acquisition
by MSKCC or any of its Affiliates of any of the Company’s equity securities representing in aggregate more than one percent
(1%) of outstanding voting power in shares of the Company, or rights or options to acquire interests in any of the Company’s
equity securities representing in aggregate more than one percent (1%) of outstanding voting power in shares of the Company, (iv)
any proposal by MSKCC to seek representation on the Board of Directors of the Company; or


 


 (b)          form an Exchange Act Section 13(d) “group” with any third party to take any of the actions set forth in Section
4.1(a);


 


 (c)           in the case of MSKCC together with any of its Affiliates, acquire (or propose or agree to acquire), of record
or beneficially, by purchase or otherwise, any equity securities representing in aggregate more than one percent (1%) of outstanding
voting power in shares of the Company, or rights or options to acquire interests in any of the Company’s equity securities
representing in aggregate more than one percent (1%) of outstanding voting power in shares of the Company.


 



    12


     


    

 


4.2           Voting. MSKCC shall be present for quorum purposes at the 2015 annual shareholders meeting of the Company and vote their
shares of Common Stock in favor of the Company’s proposal to approve an amendment to the Actinium Pharmaceuticals, Inc.
2013 Amended and Restated Stock Plan, as amended (the “Plan”), to increase the shares of Common Stock available
for issuance thereunder by three million, five hundred thousand (3,500,000) shares. The Company hereby agrees that until the earlier
to occur of (a) MSKCC beneficially owning five percent (5%) or less of the outstanding Common Stock and (b) December 31, 2016,
the Company shall not (i) issue any option under the Plan with a per share exercise price lower than what is required by Section
9 of the Plan (without giving effect to any amendments to that Section following the date hereof), except as permitted under Section
14 of the Plan (relating to certain adjustments and corporate transactions) or (ii) grant any stock purchase rights under (or
otherwise issue shares pursuant to) the Plan that entitles the recipient to shares at a purchase price less than one hundred percent
(100%) of the Fair Market Value (as defined in the Plan) per share on the date of such grant.


 


5.            Miscellaneous.


 


5.1           Successors and Assigns. The rights under this Agreement may be assigned (but only with all related obligations expressly
applicable to all Holders) by a Holder to a transferee of Registrable Securities that (a) is an Affiliate of such Holder; (b)
is a trust for the benefit of such Holder; or (c) after such transfer, holds at least five hundred thousand (500,000) shares of
Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations);
provided, however, that (i) the Company is, within a reasonable time after such transfer, furnished with written
notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred;
and (ii) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions
of this Agreement expressly applicable to Holders, including the provisions of Sections 2.10 and 4.1. For the
purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (x)
that is an Affiliate of a Holder, (y) that is a trust for the benefit of a Holder, or (z) that is a member of the immediate family
of the Holder (or a trust for the benefit of such member) shall be aggregated together and with those of such Holder. The terms
and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees
of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto
or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of
this Agreement, except as expressly provided herein.


 


5.2           Governing Law. This Agreement shall be governed by the internal law of the State of New York.


 


5.3           Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic
mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com)
or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid
and effective for all purposes.


 



    13


     


    

 


5.4           Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered
in construing or interpreting this Agreement.


 


5.5           Notices. All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be
deemed effectively given upon the earlier of actual receipt or (a) personal delivery to the party to be notified; (b) five (5)
days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (c) one (1) business
day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery,
with written verification of receipt. All communications shall be sent to the respective parties at their addresses as set forth
below (or at such other address for a party as shall be specified in a notice given in accordance with this Section 5.5):


 


	If
    to the Company:	Actinium
Pharmaceuticals, Inc.

757 3rd Ave, 21st Floor

New York, NY 10017

        Attention:
        Kaushik J. Dave, Chief Executive Officer

        Email: kdave@actiniumpharma.com

         

	With
    a copy to:	Boies
                                         Schiller & Flexner, LLP,

                                         575 Lexington Ave, 7th Floor,

                                         New York, NY, 10022,

                                         Facsimile: 212-446-2350

                                         Attention: Mike Huang

                                         Email: mhuang@bsfllp.com

         

        and

         

        The
Matt Law Firm, PLLC

1701 Genesee Street

Utica, NY 13501

Facsimile: 315-624-7359

Attention: Thomas R. Slusarczyk

Email: tslusarczyk@mattlawfirm.com

         

	If
    to MSKCC:	Memorial
Sloan Kettering Cancer Center 

        1275
        York Avenue,

        

        New
        York, NY 10065

        

        Telephone:
212-639-5800 

        Email:
        parkerr@mskcc.org

        

        Attn:
        Roger Parker, Executive Vice President and Chief Legal Officer




 



    14


     


    

 


	With
    a copy to: 	Olshan
    Frome Wolosky, LLP,

    Park Avenue Tower, 

    65 East 55th St, 

    New York, NY 10022

    Facsimile: 212-451-2222

    Attn: Mitchell Raab

    Email: mraab@olshanlaw.com


 


5.6           Amendments
and Waivers. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived
(either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of
the Company and the Holders of a majority of the Registrable Securities then outstanding; provided that any such
amendment or waiver that by its explicit terms would alter or change the right or obligations of any Holder in a
disproportionate and adverse manner compared to the rights and obligations of the other Holders shall require the written
consent of such Holder that is being so disproportionately and adversely treated, provided further that Sections
3.2 and 4.2 may be amended or waived only with the written consent of MSKCC and the Company, provided further
that the Company may in its sole discretion waive (a) compliance by any Holder with Section 2.10 and (b) compliance by
MSKCC with Section 3.2 and 4.2; and provided further that any provision hereof may be waived by
any waiving party on such party’s own behalf, without the consent of any other party. The Company shall give prompt
notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such
amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this Section 5.6
shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or
exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or
construed as a further or continuing waiver of any such term, condition, or provision.


 


5.7           Severability.
In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable
in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such
invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable
to the maximum extent permitted by law.


 


5.8           Aggregation of Stock. All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together
for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such
rights as among themselves in any manner they deem appropriate.


 


5.9           Entire Agreement. This Agreement constitutes the full and entire understanding and agreement among the parties with respect
to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the
parties is expressly canceled.


 



    15


     


    

 


5.10          Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts
of New York and to the jurisdiction of the United States District Court for the Southern District of New York for the purpose
of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action
or other proceeding arising out of or based upon this Agreement except in the state courts of New York or the United States District
Court for the Southern District of New York, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or
otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named
courts, that its property is exempt or immune from attachment or execution, that the suit, action or proceeding is brought in
an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the subject matter
hereof may not be enforced in or by such court.


 


WAIVER
OF JURY TRIAL: EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF
THIS AGREEMENT, THE OTHER TRANSACTION DOCUMENTS, THE SECURITIES OR THE SUBJECT MATTER HEREOF OR THEREOF. THE SCOPE OF THIS WAIVER
IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER
OF THIS TRANSACTION, INCLUDING CONTRACT CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON
LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE
SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH
ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL
COUNSEL.


 


5.11         Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement,
upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching
or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar
breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach
or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to
any party, shall be cumulative and not alternative.


 


5.12          Interpretation. When a reference is made in this Agreement to Articles, Sections, Schedules or Exhibits, such reference
shall be to an Article or Section of, or an Exhibit or Schedule to this Agreement, unless otherwise expressly indicated. The headings
contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this
Agreement. The words “include,” “includes” and “including” when used herein shall be deemed
in each case to be followed by the words “without limitation.” Unless the context of this Agreement otherwise requires:
(a) words of any gender include each other gender; (b) words using the singular or plural number also include the plural or singular
number, respectively; and (c) the terms “hereof”, “herein”, “hereunder” and derivative or
similar words refer to this entire Agreement, including the Exhibits and Schedules hereto. The word “or” shall not
be deemed to be exclusive. The word “Agreement” shall mean this Agreement as amended or supplemented, together with
all Exhibits and Schedules attached hereto.


 



    16


     


    

 


[Remainder
of Page Intentionally Left Blank]


 






    17


     


    

 


IN
WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.


 





	 	ACTINIUM
    PHARMACEUTICALS, INC.
	 	 	 
	 	By:	/s/
    Kaushik J. Dave
	 	Name:	Kaushik
    J. Dave
	 	Title:	Chief
    Executive Officer



  





Signature
Page to 2015 Investors’ Rights Agreement


 






    


     


    

 


	 	MEMORIAL
    SLOAN KETTERING CANCER CENTER:
	 	 	 
	 	By:	/s/
    Eric Cottington
	 	Name:	Eric
    Cottington
	 	Title:	Senior
    Vice President, Research and Technology Management












 


Signature
Page to 2015 Investors’ Rights Agreement


 






    


     


    

 


EXHIBIT A


 


Form
Of Press Release